Review
Hematology
Edward J. Bataillard, Chan Yoon Cheah, Matthew J. Maurer, Arushi Khurana, Toby A. Eyre, Tarec Christoffer El-Galaly
Summary: The dilemma of using full or reduced dose intensity of R-CHOP in elderly patients with DLBCL was studied through a systematic review. Lower dose intensity was associated with poorer survival outcomes in most studies, especially in patients aged <80 years. However, elderly patients aged >= 80 years did not show consistent impact on survival outcomes with reduced dose intensity, suggesting full-dose R-CHOP may be more appropriate in this age group. Additional DI-specific randomized trials are needed for further confirmation.
Article
Medicine, General & Internal
Yuka Morita, Yusuke Kanemasa, Yuki Sasaki, An Ohigashi, Taichi Tamura, Shohei Nakamura, Yu Yagi, Akihiko Kageyama, Yasushi Omuro, Tatsu Shimoyama
Summary: Maintaining relative dose intensity of R-CHOP improves prognosis in DLBCL patients. After approval of Pegfilgrastim, the incidence of FN decreased, and the RDI of R-CHOP increased, resulting in better overall survival and progression-free survival for patients. The use of Pegfilgrastim is important for maintaining a high RDI in high-risk DLBCL patients.
Article
Hematology
Moonho Kim, Yongchel Ahn, Heui-June Ahn, Suk-Hun Ha, Ho-Suk Oh, Jae-Seok Song, Woong-Sub Park, Sang-Wook Yi
Summary: Primary prophylaxis with long-acting granulocyte colony-stimulating factor (G-CSF) reduced the risk of febrile neutropenia-related hospitalization in DLBCL patients receiving R-CHOP, but did not benefit survival.
ANNALS OF HEMATOLOGY
(2023)
Review
Oncology
Katsuhiro Miura, Hiromichi Takahashi, Masaru Nakagawa, Takashi Hamada, Yoshihito Uchino, Kazuhide Iizuka, Shimon Ohtake, Noriyoshi Iriyama, Yoshihiro Hatta, Hideki Nakamura
Summary: This review provides the latest insights on the optimal dose intensity of R-CHOP in DLBCL treatment. It discusses the ideal dose intensity for different patient groups, such as elderly patients and those with limited or advanced-stage diseases. The review also explores the potential role of dose-intensified therapies and targeted inhibitors in DLBCL treatment.
EXPERT REVIEW OF ANTICANCER THERAPY
(2022)
Article
Public, Environmental & Occupational Health
Matthew S. Painschab, Racquel Kohler, Stephen Kimani, Wilberforce Mhango, Bongani Kaimila, Takondwa Zuze, Victor Mithi, Edwards Kasonkanji, Noel Mumba, Richard Nyasosela, Stephanie Wheeler, Satish Gopal
Summary: The study evaluated the cost-effectiveness of DLBCL treatment in Malawi, demonstrating that CHOP is cost-effective at the patient level, and the addition of rituximab may also be cost-effective.
LANCET GLOBAL HEALTH
(2021)
Article
Oncology
Grzegorz S. Nowakowski, Annalisa Chiappella, Randy D. Gascoyne, David W. Scott, Qingyuan Zhang, Wojciech Jurczak, Muhit Ozcan, Xiaonan Hong, Jun Zhu, Jie Jin, David Belada, Juan Miguel Bergua, Francesco Piazza, Heidi Mocikova, Anna Lia Molinari, Dok Hyun Yoon, Federica Cavallo, Monica Tani, Kazuhito Yamamoto, Koji Izutsu, Koji Kato, Myron Czuczman, Sarah Hersey, Adrian Kilcoyne, Jacqueline Russo, Krista Hudak, Jingshan Zhang, Steve Wade, Thomas E. Witzig, Umberto Vitolo
Summary: The ROBUST study aimed to compare the efficacy of lenalidomide plus R-CHOP with placebo/R-CHOP in previously untreated ABC-type DLBCL. While the primary end point of progression-free survival (PFS) was not met in all patients, there were trends favoring R2-CHOP over placebo/R-CHOP in patients with higher-risk disease. The safety profile of R2-CHOP was consistent with individual treatments with no new safety signals.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Article
Oncology
Shin Lee, Kei Fujita, Tetsuji Morishita, Eiju Negoro, Hikaru Tsukasaki, Kana Oiwa, Takeshi Hara, Hisashi Tsurumi, Takanori Ueda, Takahiro Yamauchi
Summary: This study found that maintaining a high average relative dose intensity (ARDI) during chemotherapy cycles is important for the prognosis of diffuse large B-cell lymphoma. However, increasing ARDI in the later cycles does not have an impact on the prognosis. Significant reduction in ARDI during early treatment cannot be counteracted by later increase in ARDI. Malnutrition is associated with adverse patterns of ARDI changes.
Article
Dermatology
Ji Yun Lee, Minsu Kang, Koung Jin Suh, Ji-Won Kim, Se Hyun Kim, Jin Won Kim, Yu Jung Kim, Kyoung-Ho Song, Eu Suk Kim, Hong Bin Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee, Jeong-Ok Lee
Summary: This study found that PCP prophylaxis is highly effective in preventing PCP infection in DLBCL patients undergoing R-CHOP treatment, which can guide prevention strategies for PCP.
Article
Oncology
Chong Wei, Yan Zhang, Wei Wang, Wei Zhang
Summary: Substituting PEG-rhG-CSF for short-acting rhG-CSF in the DA-EPOCH regimen significantly reduces the incidence of febrile neutropenia and related hospitalization, while simplifying management for both patients and healthcare providers.
CANCER MANAGEMENT AND RESEARCH
(2021)
Article
Oncology
Clemence Canton, Olayide Boussari, Mathieu Boulin, Karine Le Malicot, Julien Taieb, Laetitia Dahan, Anthony Lopez, Come Lepage, Jean-Baptiste Bachet
Summary: This study assessed the impact of granulocyte-colony stimulating factor (G-CSF) prophylaxis on dose-intensity (DI) and the relationship between DI and progression-free survival (PFS) in metastatic pancreatic adenocarcinoma. The results showed that G-CSF prophylaxis was associated with a higher rate of full DI in one chemotherapy regimen and a lower rate in another regimen. However, the association between full DI and PFS was not significant in both regimens. Further prospective confirmation is needed.
Article
Medicine, Research & Experimental
Yuqin Song, Hui Zhou, Huilai Zhang, Wei Liu, Yuerong Shuang, Keshu Zhou, Fangfang Lv, Hao Xu, Jianfeng Zhou, Wei Li, Huaqing Wang, Hongyu Zhang, Haiwen Huang, Qingyuan Zhang, Wei Xu, Zheng Ge, Ying Xiang, Shuye Wang, Da Gao, Shun'e Yang, Jinying Lin, Lin Wang, Liqun Zou, Meifang Zheng, Jing Liu, Zonghong Shao, Ying Pang, Ruixiang Xia, Zhendong Chen, Ming Hou, Hongxia Yao, Ru Feng, Zhen Cai, Mingzhi Zhang, Wenhua Ran, Lin Liu, Shan Zeng, Wei Yang, Peng Liu, Aibin Liang, Xuelan Zuo, Qingfeng Zou, Junxun Ma, Wei Sang, Ye Guo, Wei Zhang, Yongqing Cao, Yan Li, Jifeng Feng, Xin Du, Xiaohong Zhang, Hongguo Zhao, Hui Zhou, Jie Yu, Xing Sun, Jun Zhu, Lugui Qiu
Summary: The study demonstrated that IBI301 and rituximab showed similar efficacy and safety in previously untreated DLBCL patients, indicating that IBI301 plus CHOP could be a potential treatment regimen for this patient population.
ADVANCES IN THERAPY
(2021)
Article
Oncology
Zola Musimar, Mtonga Mpetani, Jeremy S. Abramson, Bruce A. Chabner, Zainab Mohamed
Summary: This retrospective cohort study found that treatment of DLBCL with R-CHOP, including rituximab, can achieve good outcomes in resource-limited settings. In this HIV-negative patient cohort, poor performance status was the most important adverse prognostic factor.
Article
Hematology
Jeffrey P. Ward, Melissa M. Berrien-Elliott, Felicia Gomez, Jingqin Luo, Michelle Becker-Hapak, Amanda F. Cashen, Nina D. Wagner-Johnston, Kami Maddocks, Matthew Mosior, Mark Foster, Kilannin Krysiak, Alina Schmidt, Zachary L. Skidmore, Sweta Desai, Marcus P. Watkins, Anne Fischer, Malachi Griffith, Obi L. Griffith, Todd A. Fehniger, Nancy L. Bartlett
Summary: This study reports the results of a trial evaluating the combination of brentuximab vedotin and lenalidomide as a potential treatment option for patients with relapsed/refractory diffuse large B-cell lymphoma. The combination demonstrated good tolerability and promising activity, with the highest response rates observed in CD30-positive DLBCL patients.
Article
Oncology
Joo Y. Song, Anamarija M. Perry, Alex F. Herrera, Lu Chen, Pamela Skrabek, Michel R. Nasr, Rebecca A. Ottesen, Janet Nikowitz, Victoria Bedell, Joyce Murata-Collins, Yuping Li, Christine McCarthy, Raju Pillai, Jinhui Wang, Xiwei Wu, Jasmine Zain, Leslie Popplewell, Larry W. Kwak, Auayporn P. Nademanee, Joyce C. Niland, David W. Scott, Qiang Gong, Wing C. Chan, Dennis D. Weisenburger
Summary: Detailed genomic analysis of 87 cases of GCB DLBCL identified four distinct biological subgroups with different survivals. A practical schema was proposed to risk-stratify patients with GCB DLBCL and to identify high-risk patients for new and innovative therapies.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Grzegorz S. Nowakowski, Fangxin Hong, David W. Scott, William R. Macon, Rebecca L. King, Thomas M. Habermann, Nina Wagner-Johnston, Carla Casulo, James L. Wade, Gauri G. Nagargoje, C. M. Reynolds, Jonathon B. Cohen, Nadia Khan, Jennifer E. Amengual, Kristy L. Richards, R. F. Little, John P. Leonard, Jonathan W. Friedberg, Lale Kostakoglu, Brad S. Kahl, Thomas E. Witzig
Summary: The addition of lenalidomide to R-CHOP (R2CHOP) in newly diagnosed DLBCL, particularly in the ABC-DLBCL subtype, showed improved outcomes including better progression-free survival and overall survival rates. This study suggests that R2CHOP may be an effective treatment option for patients with DLBCL, especially those with the ABC-DLBCL subtype.
JOURNAL OF CLINICAL ONCOLOGY
(2021)